GCG and type 2 diabetes mellitus: Therefore, the 2022 KDIGO guidelines recommend long-acting GLP-1 RAs with established cardiovascular (CV) benefits as the preferred second-line therapy for glycemic control and CV risk reduction in adults with type 2 diabetes with established cardiovascular disease (CVD) or a high CV risk profile.